Integrated Bioinformatics Analysis Revealed Immune Checkpoint Genes Relevant to Type 2 Diabetes
DOI: https://doi.org/10.2147/dmso.s458030
2024-06-12
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Ziteng Zhang, Guoting Sun, Yuying Wang, Ningjian Wang, Yingli Lu, Yi Chen, Fangzhen Xia Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China Correspondence: Fangzhen Xia; Yi Chen, Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Zhizaoju road No. 639, Shanghai, 200011, People's Republic of China, Tel +86 21 23271699-5256, Email ; Objective: Chronic low-grade inflammation of the pancreatic islets is the characteristic of type 2 diabetes (T2D), and some of the immune checkpoints may play important roles in the pancreatic islet inflammation. Thus, we aim to explore the immune checkpoint genes (ICGs) associated with T2D, thereby revealing the role of ICGs in the pathogenesis of T2D based on bioinformatic analyses. Methods: Differentially expressed genes (DEGs) and immune checkpoint genes (ICGs) of islets between T2D and control group were screened from datasets of the Gene Expression Omnibus (GEO). A risk model was built based on the coefficients of ICGs calculated by ridge regression. Functional enrichment analysis and immune cell infiltration estimation were conducted. Correlations between ICGs and hub genes, T2D-related disease genes, insulin secretion genes, and beta cell function-related genes were analyzed. Finally, we conducted RT-PCR to verify the expression of these ICGs. Results: In total, pancreatic islets from 19 cases of T2D and 84 healthy subjects were included. We identified 458 DEGs. Six significantly upregulated ICGs (CD44, CD47, HAVCR2, SIRPA, TNFSF9, and VTCN1) in T2D were screened out. These ICGs were significantly correlated with several hub genes and T2D-related genes; furthermore, they were correlated with insulin secretion and β cell function-related genes. The analysis of immune infiltration showed that the concentrations of eosinophils, T cells CD4 naive, and T cells regulatory (Tregs) were significantly higher, but CD4 memory resting T cells and monocytes were lower in islets of T2D patients. The infiltrated immune cells in T2D pancreatic islet were associated with these six ICGs. Finally, the expression levels of four ICGs were confirmed by RT-PCR, and three ICGs were validated in another independent dataset. Conclusion: In conclusion, the identified ICGs may play an important role in T2D. Identification of these differential genes may provide new clues for the diagnosis and treatment of T2D. Keywords: type 2 diabetes, immune checkpoint gene, bioinformatics, microenvironment Diabetes has become one of the most serious public health problems in the world with its increasing morbidity and mortality. There are about 537 million adults worldwide with diabetes, and approximately 90% of them have T2D. 1 Increasing evidence showed that chronic low-grade inflammation and innate immune system activation are contributed to the pathogenesis of T2D 2 and some anti-inflammatory agents may have effects on T2D, such as aspirin 3 and interleukin-1 receptor antagonist. 4 However, the specific mechanisms about the activation and regulation of this inflammatory state in T2D remain unclear. Therefore, figuring out how the pancreatic islet inflammation modulates the progression of T2D may provide a new insight into the pathogenesis of T2D. Immune checkpoints, most of which are inhibitory pathways in the immune system, are critical to keep self-tolerance and regulate type, intensity, and duration of immune response. 5 Immune checkpoint blockade (ICB) therapy with the use of inhibitors, which target different immune checkpoints, has emerged as a promising therapy in the treatment of several types of cancer, such as gastric cancer, 6 hepatocellular carcinoma, 7 and pancreatic cancer. 8 As potential treatment targets for ICB therapy, immune checkpoint genes (ICGs) are involved in immune pathways, and the expression levels of ICGs are important biomarkers for ICB therapy; 9 however, it is not well investigated in the field of T2D. Several studies reported that immune checkpoint inhibitors induced diabetes or aggravated pre-existing T2D. 10,11 Also, a recent study showed that CD24 -Siglec-E interaction is a protective immune checkpoint against metabolic dysfunction and metaflammation, 12 suggesting that immune checkpoint molecules may be involved in the pathogenesis of T2D. Meanwhile, Sun et al found that PD-1 expression levels on immune cells were significantly lower in patients with T2D but were positively associated with insulin levels and duration of diabetes. 13 However, the roles of imm -Abstract Truncated-
endocrinology & metabolism